Table 2 Serum biochemistry and in vitro lipid transfers to HDL data of the group of patients with class I/II and III/IV heart failure (HF)
HF I/II (n = 25) | HF III/IV (n = 23) | p-value | p-value b | |
|---|---|---|---|---|
BNP (pg/mL) | 265 ± 77 (144–401) | 1066 ± 621 (531–3350) | < 0.001 a | < 0.001 c |
Glucose (mg/dL) | 96 ± 14 (78–125) | 115 ± 33 (79–231) | 0.008 a | 0.002 c |
Insulin (pg/mL) | 362 ± 246 (48–887) | 532 ± 795 (37–3426) | 0.757 a | 0.061 c |
Leptin (pg/mL) | 34,000 ± 35,082 (2229–118,501) | 16,286 ± 25,517 (440–96,772) | 0.004 a | 0.090 c |
Triglycerides (mg/dL) | 119 ± 33 (61–193) | 120 ± 50 (55–278) | 0.726 a | 0.697 c |
Cholesterol (mg/dL) | ||||
Total | 192 ± 38 (105–274) | 170 ± 37 (105–269) | 0.049 | 0.031 |
LDL | 143 ± 35 (70–228) | 118 ± 38 (52–222) | 0.023 | 0.013 |
non-HDL | 167 ± 39 (82–254) | 141 ± 39 (76–249) | 0.029 | 0.016 |
HDL | 25 ± 6 (17–41) | 28 ± 11 (17–65) | 0.351 a | 0.252 c |
Apolipoproteins (mg/dL) | ||||
A-I | 126 ± 23 (80–162) | 133 ± 31 (96–217) | 0.388 | 0.392 c |
B | 92 ± 27 (57–161) | 81 ± 35 (25–165) | 0.230 | 0.175 |
Oxidized LDL (U/L) | 51.55 ± 22.22 (17.20–101.20) | 40.79 ± 20.72 (11.70–78.50) | 0.089 | 0.070 |
PON-1 (nmol/min/mL) | 111.96 ± 62.66 (21.60–245.50) | 132.91 ± 81.07 (29.70–315.10) | 0.427 a | 0.147 c |
LCAT (μg/mL) | 8.43 ± 2.28 (4.00–11.60) | 8.26 ± 3.32 (3.30–15.80) | 0.842 | 0.498 |
CETP (μg/mL) | 3.73 ± 1.30 (1.33–5.52) | 2.77 ± 1.30 (0.81–5.26) | 0.013 | 0.002 |
Lipid Transfers (%) | ||||
Esterified cholesterol | 5.97 ± 0.82 (4.07–7.60) | 5.44 ± 1.76 (2.61–9.44) | 0.192 | 0.275 |
Unesterified cholesterol | 6.73 ± 1.12 (4.33–9.89) | 6.29 ± 2.05 (3.07–9.78) | 0.363 | 0.455 |
Phospholipids | 19.91 ± 1.12 (17.33–22.59) | 19.05 ± 2.50 (14.16–23.85) | 0.139 | 0.122 |
Triglycerides | 8.45 ± 1.31 (6.28–11.69) | 8.07 ± 2.27 (4.31–11.89) | 0.504 | 0.900 |